Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI technique could spot dangerous placenta adhesions before delivery

NCT ID NCT04328532

Diagnosis Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial investigates whether advanced MRI scans can better detect placenta adhesion abnormalities (PAA) in pregnant women between 30 and 38 weeks. PAA occurs when the placenta grows too deeply into the uterine wall, raising risks of severe bleeding and emergency hysterectomy during delivery. The study uses special MRI measurements to assess placental blood flow and oxygen levels without contrast dye, aiming to improve diagnosis beyond standard ultrasound.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this MRI technique could provide a safer, more accurate way to detect dangerous placenta adhesions before delivery, potentially reducing severe bleeding and emergency surgeries.
What could go wrong
This is a small, early-stage diagnostic study. The MRI method may not prove more accurate than standard ultrasound, and results may not apply to all pregnant women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 71 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2020

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant participant between 30 and 38 weeks of gestation, * Age ≥18 years old, * Participant who completed the preliminary medical examination, * Participant who has received full information about the organization of the research and has signed her informed consent. * Participant planning to give birth at CHRU of Nancy * Participant presenting risk factors for PAA : low-lying or covering placenta or in front of the uterine scar. Exclusion Criteria: * Multiple pregnancy, * Participant presenting at least one contraindication or restriction to performing an MRI as described in the protocol, in accordance with the current recommendations, * Participant unable to understand or follow study procedure, * Person referred to in Articles L. 1121-6 to L. 1121-8, L1122-2 and L. 1122-1-2 of the Public Health Code.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Placenta adhesion abnormality are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

placenta accreta

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Placenta; implantation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Régional Universitaire de Nancy

    RECRUITING

    Vandœuvre-lès-Nancy, 54500, France